Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse
- 13 December 2010
- journal article
- research article
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 28 (2), 137-144
- https://doi.org/10.1002/da.20768
Abstract
Many patients with major depressive disorder (MDD) who achieve full remission after antidepressant treatment still have residual depressive symptoms. In this study, we assess the type and frequency of residual symptoms and their relationship to subsequent depressive relapses after remission of major depression with fluoxetine. Five hundred seventy-six patients with MDD were openly treated with fluoxetine for 12 weeks. Those who responded underwent random assignment, under double-blind conditions, to continue taking fluoxetine or to switch to placebo for 52 weeks or until relapse. The presence of residual symptoms in patients who achieved remission at the end of the acute phase (N=203) was assessed using the 28-item Hamilton Depression Rating Scale. Survival analysis was used to examine the effect of residual symptoms on relapse in remitters. More than 90% of patients who met criteria for remission had at least one residual depressive symptom (median=4). The most common were sleep disturbances (insomnia 48.2%, hypersomnia 35.9%) and anxiety (52.7%). The most common individual symptom was middle insomnia (33.5%). No statistically or clinically significant differences in baseline variables were found between remitters with and without residual symptoms. The presence of residual symptoms, the presence of residual insomnia and the global number of residual symptoms did not predict relapse during the continuation phase of the study. The great majority of patients with remission of MDD after treatment with fluoxetine continue to experience selected residual depressive symptoms. The presence of residual symptoms is not significantly associated with an increased risk of relapse.Keywords
This publication has 36 references indexed in Scilit:
- A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XRJournal of Clinical Psychopharmacology, 2008
- Major Depression Symptoms in Primary Care and Psychiatric Care Settings: A Cross-Sectional AnalysisAnnals of Family Medicine, 2007
- Residual Anxiety Symptoms in Depressed Primary Care PatientsJournal of Psychiatric Practice, 2007
- Long‐term social functioning after depression treated by psychiatrists: a reviewBipolar Disorders, 2007
- The concept of recovery in major depressionPsychological Medicine, 2006
- Primary insomnia: a risk factor to develop depression?Journal of Affective Disorders, 2003
- Does Incomplete Recovery From First Lifetime Major Depressive Episode Herald a Chronic Course of Illness?American Journal of Psychiatry, 2000
- A Multicenter, Double-Blind Comparison of the Effects of Nefazodone and Fluoxetine on Sleep Architecture and Quality of Sleep in Depressed OutpatientsJournal of Clinical Psychopharmacology, 1997
- Fluoxetine-Induced Sleep Disturbance in Depressed PatientsNeuropsychopharmacology, 1996
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960